Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations

Chronic stable angina pectoris is the primary indication for ranolazine (RZ), an anti-anginal drug. The drug has an anti-ischemic action that is unaffected by either blood pressure or heart rate. Due to the first-pass effect, the drug has a reduced bioavailability of 35 to 50%. The study emphasized developing a novel transdermal drug delivery system of nanostructured lipid carriers (NLCs) for delivering RZ. Many pharmaceutical companies employ lipid nanoparticles as biocompatible carriers for medicinal, cosmetic, and biochemical uses. These carriers are appropriate for many applications, such as topical, transdermal, parenteral, pulmonary, and oral administration, because of the large variety of lipids and surfactants that are readily available for manufacturing. RZ NLCs were made using high-pressure homogenization. Statistical analysis was utilized to find the best formula by varying the concentrations of Precirol ATO 5 (X1), oleic acid (X2), and Tween 80 (X3). Variables such as entrapment effectiveness (EE) (Y1), particle size (Y2), polydispersity index (PDI) (Y3), and zeta potential (Y4) were tested. A variety of tests were performed on the new formulation to ascertain how well it would be absorbed in the body. These tests included in vivo absorption studies, skin permeability assessments, in vitro drug release assessments, and physicochemical analyses. The particle size of RZ-NLCs was shown to be very small (118.4 ± 5.94 nm), with improved EE (88.39 ± 3.1%) and low ZP and PDI (−41.91 ± 0.38 and 0.118 ± 0.028). SEM and TEM analysis confirmed the structure of the NLCs and showed a smooth, spherical surface. Improved RZ-NLCs were used to create NLC gel, which was then tested for elasticity both physically and rheologically. The formulation’s elasticity was investigated. Optimized RZ-NLCs and NLCG were found to have transdermal fluxes of 48.369 g/cm2/h and 38.383 g/cm2/h, respectively. These results showed that the transdermal delivery of RZ distribution through NLC’s transdermal gel had more significant potential. According to in vivo experiments, the drug’s bioavailability in Wistar rats increased when it was delivered through NLCs. The findings demonstrated that NLCs loaded with RZ successfully transported the RZ to the designated site with no interruptions and that a quadratic connection existed between the independent and dependent variables.

[1]  R. Brandes,et al.  Experimental uninephrectomy associates with less parasympathetic modulation of heart rate and facilitates sodium-dependent arterial hypertension , 2022, PloS one.

[2]  J. Thireau,et al.  Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning , 2021, Pharmaceuticals.

[3]  Padmanabha Rao Amarachinta,et al.  Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect , 2021, Journal of Nanobiotechnology.

[4]  José Juan Escobar-Chávez,et al.  Transdermal Delivery Systems for Biomolecules , 2021, Journal of pharmaceutical innovation.

[5]  A. Chettupalli,et al.  Nanocrystals: Characterization Overview, Applications in Drug Delivery, and Their Toxicity Concerns , 2020, Journal of Pharmaceutical Innovation.

[6]  S. Mohammadi-Samani,et al.  Potential of Nanoparticles as Permeation Enhancers and Targeted Delivery Options for Skin: Advantages and Disadvantages , 2020, Drug design, development and therapy.

[7]  B. Forbes,et al.  Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters , 2020, Pharmaceutics.

[8]  Sarwar Beg,et al.  Pharmaceutical Drug Product Development and Process Optimization , 2020 .

[9]  K. Dua,et al.  Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast , 2020, Dermatologic therapy.

[10]  M. Yasir,et al.  Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery , 2020, Advanced pharmaceutical bulletin.

[11]  V. Sharma,et al.  Rational design and in-vivo estimation of Ivabradine Hydrochloride loaded nanoparticles for management of stable angina , 2019 .

[12]  S. S. Imam,et al.  Formulation of amlodipine nano lipid carrier: Formulation design, physicochemical and transdermal absorption investigation , 2019, Journal of Drug Delivery Science and Technology.

[13]  Mayur M. Patel,et al.  Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis , 2018, Drug development and industrial pharmacy.

[14]  R. Ferrari,et al.  Treatment of Angina: Where Are We? , 2018, Cardiology.

[15]  Karthik Yadav Janga,et al.  Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation , 2018, Artificial cells, nanomedicine, and biotechnology.

[16]  James R. Smith,et al.  Liposomal Drug Delivery Systems and Anticancer Drugs , 2018, Molecules.

[17]  A. Chauhan Dendrimers for Drug Delivery , 2018, Molecules.

[18]  Neel N. Shah,et al.  Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease , 2018, Drug development and industrial pharmacy.

[19]  C. Ghelardini,et al.  Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy , 2018, Drug delivery.

[20]  Alexander M. Kiel,et al.  Regulation of Coronary Blood Flow. , 2017, Comprehensive Physiology.

[21]  A. Ahad,et al.  Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study , 2017, Artificial cells, nanomedicine, and biotechnology.

[22]  A. Ahad,et al.  Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. , 2016, International journal of pharmaceutics.

[23]  B. Gidwani,et al.  Nanostructured lipid carriers and their current application in targeted drug delivery , 2016, Artificial cells, nanomedicine, and biotechnology.

[24]  M. Singh,et al.  Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders , 2016, Artificial cells, nanomedicine, and biotechnology.

[25]  J. Pizzorno,et al.  The Clinician's Handbook of Natural Medicine , 2015 .

[26]  S. S. Imam,et al.  Formulation by design-based proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study , 2015, Drug delivery.

[27]  T. Garg,et al.  Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor , 2015, Journal of drug targeting.

[28]  Neeraj Kumar,et al.  Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment. , 2014, International journal of pharmaceutics.

[29]  M. Serin,et al.  Histopathological evaluation of melatonin as a protective agent in heart injury induced by radiation in a rat model. , 2014, Pathology, research and practice.

[30]  R. Shamma,et al.  Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia , 2014, International journal of nanomedicine.

[31]  Ding-Yuan Chen,et al.  Injectable Cell Constructs Fabricated via Culture on a Thermoresponsive Methylcellulose Hydrogel System for the Treatment of Ischemic Diseases , 2014, Advanced healthcare materials.

[32]  Tarun Goyal Liposomes: Targeted and Controlled Delivery System , 2014 .

[33]  V. Patravale,et al.  Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. , 2013, International journal of pharmaceutics.

[34]  E. Oh,et al.  Formulation and optimization of spray-dried amlodipine solid dispersion for enhanced oral absorption , 2013, Drug development and industrial pharmacy.

[35]  Tarun Goyal Iontophoresis: Drug Delivery System by Applying an Electrical Potential Across the Skin , 2012 .

[36]  R. B. Walker,et al.  Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers. , 2011, Journal of pharmaceutical sciences.

[37]  R. Tan,et al.  Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. , 2011, Colloids and surfaces. B, Biointerfaces.

[38]  R. Müller,et al.  Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance. , 2011, International journal of pharmaceutics.

[39]  S. Chan,et al.  Nanosized ethosomes bearing ketoprofen for improved transdermal delivery. , 2011, Results in pharma sciences.

[40]  E. Carlson,et al.  Human Biology and Health , 2009, The Quarterly Review of Biology.

[41]  Xiaoning Zhang,et al.  Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. , 2010, International journal of pharmaceutics.

[42]  V. Patravale,et al.  Microemulsion based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation. , 2009, International journal of pharmaceutics.

[43]  Pál Pacher,et al.  Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats , 2008, Nature Protocols.

[44]  I. Antal,et al.  Application of sucrose fatty acid esters in transdermal therapeutic systems. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[45]  M. Matsubara,et al.  Effects of benidipine in a rat model for experimental angina. , 2006, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[46]  V. Patravale,et al.  Formulation and Evaluation of Nanostructured Lipid Carrier (NLC)–based Gel of Valdecoxib , 2006, Drug development and industrial pharmacy.

[47]  Jean-Claude Tardif,et al.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. , 2005, European heart journal.

[48]  J. Wondergem,et al.  Effects of Amifostine on Radiation-induced Cardiac Damage , 2003, Acta oncologica.

[49]  G. Lewith The Clinician's Handbook of Natural Medicine , 2002 .

[50]  J. Montani,et al.  Direct and indirect methods used to study arterial blood pressure. , 2000, Journal of pharmacological and toxicological methods.

[51]  N. Peppas,et al.  Mechanisms of solute release from porous hydrophilic polymers , 1983 .

[52]  Processed Cheese Science and Technology , 2022 .

[53]  V. Kishan,et al.  Preparation, Characterization and in vivo Evaluation of Felodipine Solid-Lipid Nanoparticles for Improved Oral Bioavailability , 2015 .

[54]  G. Reena,et al.  Formulation Development and Characterization of Modified Release Microspheres of Antianginal Drug , 2015 .

[55]  P. M. Dandagi,et al.  FORMULATION AND EVALUATION OF NANOSTRUCTURED LIPID CARRIER (NLC) OF LORNOXICAM , 2014 .

[56]  Xinsheng Peng,et al.  Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design , 2011 .

[57]  Bridget B. Kelly,et al.  Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries , 2010 .

[58]  D. Favarato,et al.  Chronic coronary artery disease , 1999 .

[59]  N. Peppas Analysis of Fickian and non-Fickian drug release from polymers. , 1985, Pharmaceutica acta Helvetiae.

[60]  R. Berne,et al.  REGULATION OF CORONARY BLOOD FLOW. , 1964, Physiological reviews.